MedAI Verdict

Clinical Decision Support · 57 tools

Editorial illustration: a magnifying glass over an anatomical heart, with a branching differential-diagnosis tree leading to ischemic, valvular, and inflammatory etiologies.

Anumana

Anumana logo
21/ 100

Evidence & Documentation Score

This legacy score reflects documented evidence, integrations, transparency, and market signals. It does not measure overall product performance. A new product-focused rating system is in development. How it is computed

reviewed November 2, 2026

Vendor
Anumana, US
Pricing
No public price. The pricing page returns 404; the site offers a demo request only.
EHR
Not stated
Compliance
FDA 510(k)

Bottom line. Anumana, a Mayo Clinic and nference joint venture based in Cambridge, Massachusetts, sells ECG-AI algorithms that read a standard 12-lead ECG and send a clinical decision support notification into the EHR. It holds four 510(k) clearances for low ejection fraction, pulmonary hypertension and cardiac amyloidosis. It suits a health system that wants those flags raised from 12-lead ECGs it already… Read the full bottom line

Visit Anumana (opens in new tab)

FDA 510(k) · 3 papers

Performance profile

  • Regulatory and compliance12 / 22
  • Clinical integration0 / 11.6
  • Evidence strength0 / 30
  • Vendor and market3 / 12
  • Sentiment and transparency1.3 / 2.5

Performance profile

  • Regulatory and compliance12 / 22
  • Clinical integration0 / 11.6
  • Evidence strength0 / 30
  • Vendor and market3 / 12
  • Sentiment and transparency1.3 / 2.5
On this page

All 9 dimensions

Regulatory and compliance

  • FDA clearance12 / 12

    FDA cleared (4 510(k) clearances on record)

  • HIPAA / SOC2 / BAA0 / 10

    No public HIPAA/SOC2/BAA attestation

Clinical integration

  • EHR integrations (count)0 / 5.6

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0 / 4.8

    None of the top-3 EHRs covered

  • Bidirectional write-back0 / 1.2

    No bidirectional write-back documented

Evidence strength

  • Peer-reviewed papers0 / 21

    No peer-reviewed paper evaluating the product; 3 not counted (product only mentioned or used, or not yet classified)

  • RCT / meta-analysis / systematic review0 / 9

    No RCT, meta-analysis, or systematic review evaluating the product

Vendor and market

  • Funding & adoption signal3 / 12

    Seed-stage or unfunded

Sentiment and transparency

  • Pricing transparency1.3 / 2.5

    Pricing on request, no public amounts

Computed November 12, 2026 by our public rubric. How it’s computed

What it costs

From
No public price. The pricing page returns 404; the site offers a demo request only.
Price points
1
Verified
November 2, 2026
Source
Vendor pricing page

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price. The pricing page returns 404; the site offers a demo request only.

Source: vendor pricing page. Last checked November 2, 2026.

Compliance

Attested
FDA 510(k)
EHR integrations
Not stated
FDA
4 decisions on record

Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Vendor stability

Company
Anumana
Headquarters
US
Founded
Not stated

Vendor sitewww.anumana.ai (opens in new tab)

Evidence record

RecordWhat we found
FDA decisions
Peer-reviewed

3 studies on PubMed: 3 other, published 2023 to 2026. Read the literature summary

Verification
  • Score computed November 12, 2026, method 1.2.1
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Anumana record, https://medaiverdict.com/tools/anumana, version November 2, 2026

Change historyView every change to this record

Peer-reviewed coverage

PubMed lists 3 papers that name Anumana, shown by relevance (title match, study design, recency, journal tier). 0 of them evaluate the product itself; the others only mention it, use it as a tool or do not identify it clearly, and do not count as evidence.

YearJournalTitleAuthors
2026Am Heart J PlusA Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (ACT-HF): Clinical trial design and methods. (opens in new tab)Heart failure with reduced ejection fraction (HFrEF) is progressive and pervasive. Guidelines provide evidence-based recommendations to manage HFrEF, yet adherence to Guideline Directed Medical Therapy (GDMT) is low. An opportunity exists to improve adherence by delivering actionable data, reducing clinician information overload, and enhancing patient care. A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (ACT-HF) will evaluate a clinical decision support software (CDSS) that integrates in electronic healt…Lopez-Jimenez F, Alger HM, Hackett SP, et al.
2026Am Heart J PlusComment on "A pragmatic trial evaluating the impact of the anumana clinical decision support tool for guideline-directed management of heart failure (ACT-HF): Clinical trial design and methods". (opens in new tab)Che B, Li L
2023EClinicalMedicineIdentification and risk stratification of coronary disease by artificial intelligence-enabled ECG. (opens in new tab)Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide, driven primarily by coronary artery disease (CAD). ASCVD risk estimators such as the pooled cohort equations (PCE) facilitate risk stratification and primary prevention of ASCVD but their accuracy is still suboptimal. Using deep electronic health record data from 7,116,209 patients seen at 70+ hospitals and clinics across 5 states in the USA, we developed an artificial intelligence-based electrocardiogram analysis tool (ECG-AI) to detect CAD and assessed the additive value of ECG-AI-based ASCVD risk strati…Awasthi S, Sachdeva N, Gupta Y, et al.

See all on PubMed (opens in new tab)

Bottom line

Anumana, a Mayo Clinic and nference joint venture based in Cambridge, Massachusetts, sells ECG-AI algorithms that read a standard 12-lead ECG and send a clinical decision support notification into the EHR. It holds four 510(k) clearances for low ejection fraction, pulmonary hypertension and cardiac amyloidosis. It suits a health system that wants those flags raised from 12-lead ECGs it already acquires. Access is by demo request, so a practice that wants a posted price or a device to buy off the page is not served.

ECG-AI software that flags low ejection fraction, pulmonary hypertension and cardiac amyloidosis from standard 12-lead ECGs.

No public price. The pricing page returns 404; the site offers a demo request only.

Which FDA decisions are Anumana's?

All four are 510(k) clearances:

  • K232699 (September 28, 2023), Low Ejection Fraction AI-ECG Algorithm, product code QYE. Its predicate is Viz HCM, authorized through De Novo DEN230003 for Viz.ai, which is another company's authorization.
  • K250652 (July 28, 2025), ECG-AI Low Ejection Fraction 12-Lead algorithm.
  • K252360 (March 28, 2026), ECG-AI Pulmonary Hypertension 12-Lead algorithm, product code SAT.
  • K253801 (April 7, 2026), ECG-AI Cardiac Amyloidosis 12-Lead algorithm, product code SHP. The vendor's site dates it April 8.

Where do the algorithms appear in the literature?

Thirteen PubMed hits match the company by name or affiliation. Nine concern its work, many with Mayo and nference authors, which makes them vendor-linked. Titles name these, and whether each one tests the cleared algorithm is not verified:

  • PMID 41377035 (Am Heart J Plus, 2026), a pragmatic trial of the Anumana clinical decision support tool for guideline-directed management, with PMID 42828092 as a comment on it.
  • PMID 40276542 (Am Heart J Plus, 2025), a multicenter pragmatic implementation of AI-ECG software to identify low LVEF.
  • PMID 41547169 (JACC Advances, 2026), multisite external validation of an AI-ECG algorithm for low EF.
  • PMID 38936966 (European Respiratory Journal, 2024), ECG-based AI for early pulmonary hypertension detection.

The vendor says the low EF model was built on about 2.9 million ECG and echo pairs from more than 676,000 patients and reports 90.2% sensitivity and 85.1% specificity, attributed to its own data. It claims more than 30 peer-reviewed publications.

How does it fit into a hospital?

The vendor says the software accepts XML or DICOM waveform files, that no PHI is exported for external processing, and that the algorithms deploy within EHRs. No EHR or ECG management system is named. The homepage lists CPT III codes for charge capture and calls the product "eligible for reimbursement today". It describes low EF as available for clinical use in the US and EU and cites no CE certificate. Beyond a vulnerability disclosure page, the homepage and About page cite no security certification, and they list no price or customer.

Ownership and funding

The company launched in 2021 as a joint venture of Mayo Clinic and nference. Maulik Nanavaty is CEO and Murali Aravamudan executive chairman. MedCity News coverage reports a $25.7 million Series A at launch and a $60 million Series B by July 2022. CB Insights shows a Series C and $153.1 million in total, which is unverified.

The verdict

The homepage cites CPT III codes for charge capture and calls the product eligible for reimbursement. A buyer who wants single-lead or wearable ECG screening is in a different category.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

Link to this review

Anumana, reviewed on MedAI Verdict

Vendors may place this badge on their own site. It links to this review with a tracking parameter and has no effect on the score.

<a href="https://medaiverdict.com/tools/anumana?utm_source=vendor_badge&utm_medium=badge&utm_campaign=anumana"><img src="https://medaiverdict.com/badges/reviewed-on-medaiverdict.png" srcset="https://medaiverdict.com/badges/reviewed-on-medaiverdict@2x.png 2x" alt="Anumana, reviewed on MedAI Verdict" width="200" height="56"></a>

What we have not verified

  1. We have not run Anumana in our own clinical practice. Pricing, certifications, and EHR-integration claims come from vendor documentation and have not been independently audited.
  2. Enterprise pricing tiers and SLA terms are typically under NDA and not publicly verifiable. Numbers shown reflect publicly disclosed self-service or list pricing only.
  3. Real-world latency, note quality, and accuracy in your specific specialty and patient population can vary materially from vendor demonstrations. We recommend a 30-day trial with two providers before commitment.

Last verified . Read our methodology · Decision support